Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Hemab Therapeutics Holdings, Inc. (COAG)

Hemab Therapeutics adds Keli Walbert to board, names her to Audit Committee

Neutral Impact 2 of 5 leadership Written later

Hemab Therapeutics' board elected Keli Walbert as a director effective September 24, 2026, and also appointed her to the Audit Committee. The filing describes standard non-employee director pay, including an option for 36,000 shares and $40,000 in annual board cash compensation, which is typical for a board addition and has limited direct effect on shareholders.

Key points

  • Keli Walbert elected to the board effective September 24, 2026, as a Class I director with a term expiring at the 2027 annual meeting.
  • Walbert also joins the Audit Committee.
  • Director pay includes an option to purchase 36,000 shares at the closing price on the grant date, vesting monthly over three years.
  • Annual cash compensation is $40,000 for board service plus $10,000 for Audit Committee service.

The filing

CompanyHemab Therapeutics Holdings, Inc. (COAG)
Form8-K, current report
Filed with the SECSep 24, 2026, 4:03 PM ET
Accession number0001193125-26-401010

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 24, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.